Morgan Stanley Reiterates Rating on VIR $VIR
Key Points
- Morgan Stanley now rates Vir Biotechnology, Inc. ($VIR) "buy" with a $27.00 target.
- The Street's average $VIR price target is $21.56 (Strong Buy).
- $VIR last traded around $8.51.
Morgan Stanley reiterated its rating on Vir Biotechnology, Inc. ($VIR) to a "buy" rating, with a price target of $27.00 in a recent research note.
Vir Biotechnology, Inc. ($VIR) Stock
Vir Biotechnology, Inc. Earnings
Analysts Set New Price Targets
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.